Longbio Pharma
Clinical trials sponsored by Longbio Pharma, explained in plain language.
-
New hope for PNH: experimental drug LP-005 enters Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called LP-005 in 30 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if LP-005 can lower a key disease marker (LDH) and raise hemoglobin levels without needing bloo…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New shot for chronic hives begins safety testing
Disease control OngoingThis early-stage trial tests a single dose of LP-003, a new drug for chronic spontaneous urticaria (long-lasting hives), in 12 healthy adults. The main goal is to check safety and how the body processes the drug. It is not yet tested in people with hives.
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New allergy shot for teens shows early promise
Symptom relief OngoingThis study tests a new injection called LP-003 in 6 teenagers aged 12 to 18 who have allergies like hay fever, asthma, or eczema. The main goal is to check if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and drug levels rat…
Phase: PHASE1, PHASE2 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
New shot aims to tame tough seasonal allergies
Symptom relief OngoingThis study tests an experimental injection called LP-003 in 546 adults with moderate to severe seasonal allergic rhinitis (hay fever) that standard medications don't manage well. Participants receive either the drug or a placebo, and report their nasal symptoms daily. The goal is…
Phase: PHASE3 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC